Patients receive 131 I-MIBG IV over 120 minutes on day -21; melphalan IV on days -7 to -5;
carboplatin and etoposide IV continuously over 96 hours on days -7 to -4; autologous
hematopoietic stem cell transplantation IV over 15-30 minutes on day 0; and filgrastim
(G-CSF) subcutaneously or IV starting on day 0 and continuing until blood counts recover.
Radiotherapy is administered to the primary tumor site and metastatic sites twice daily for
7 consecutive days within 6 weeks of transplantation or once blood counts have recovered.

Cohorts of 3-6 patients receive escalating doses of 131 I-MIBG, carboplatin, and etoposide
until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at day 84, and then 2 months later if there is a complete response
and/or partial response. Patients who continue therapy on other protocols are followed
before starting the new therapy. All patients are followed for life for any delayed toxic
effects related to study therapy, secondary malignancies, disease status, and survival.

PROJECTED ACCRUAL: A total of 30-60 patients (15-30 per stratum) will be accrued for this
study within 2-3 years.

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.